Contact UsBiological Products
> Biopharmaceutical Industry Insight & News > Biological Products
| Product | Remsima? | Company | Celltrion, Inc. |
|---|---|---|---|
| Classification | Biosimilar | Active Ingredient | Infliximab |
| Reference Product | Remicade | Approval Date | 2012 |
| Indication | Rheumatoid Arthritis, Ankylosing Spondylitis, Adult Crohn’s Disease, Pediatric Crohn’s Disease, Ulcerative Colitis, Pediatric Ulcerative Colitis, Psoriatic Arthritis, Plaque Psoriasis | ||
| Description |
The world first biosimilar monoclonal antibody(mAb), approved in 79 countries including MFDS(2012), EMA(2013) and FDA(2016).
Remsima is a tumor necrosis factor α (TNF-α) antagonist used to treat rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, pediatric ulcerative colitis, adult Crohn's disease, pediatric Crohn’s disease, plaque psoriasis, and psoriatic arthritis. |
||
Korea Biomedicine Industry Association(KoBIA)
Address: 12, Teheran-ro 78-gil, Gangnam-gu, Seoul, Republic of Korea Tel: +82-2-725-8438 E-mail: info@kobia.kr
Address: 12, Teheran-ro 78-gil, Gangnam-gu, Seoul, Republic of Korea Tel: +82-2-725-8438 E-mail: info@kobia.kr
COPYRIGHT BY KoBIA. ALL RIGHTS RESERVED.